Download full text in PDF

Diab T, Adly EM, Hessien M. Dexamethasone marginally surpasses MSC-secretome in resolving acute liver failure in mice. Bìol. Tvarin. 2024; 26 (4): 12–17. DOI: 10.15407/animbiol26.04.012.
https://doi.org/10.15407/animbiol26.04.012
Received 18.08.2024 ▪ Revision 21.10.2024 ▪ Accepted 20.01.2025 ▪ Published online 22.01.2025

---

Dexamethasone marginally surpasses MSC-secretome in resolving acute liver failure in mice

Thoria Diab, Eiman M. Adly, Mohamed Hessien

This email address is being protected from spambots. You need JavaScript enabled to view it.

Molecular Cell Biology Unit, Division of Biochemistry, Faculty of Science, Tanta University, Tanta, 31527, Egypt

---

The anti-inflammatory roles of Mesenchymal stem cells (MSCs) and glucocorticoids are well-reported in both preclinical and clinical studies. However, it is not clear how far MSC-secretome offers sufficient protection against acute liver failure (ALF) compared to glucocorticoids. To answer this query, acute liver failure was induced in mice by a single toxic dose (400 mg/kg) of acetaminophen (APAP). Then mice were treated with Dexamethasone or transfused with MSC-secretome, which was derived from DEX-treated bone marrow mesenchymal stem cells. The results showed that 10 nM DEX has no impact on the viability or the mesenchymal characteristics of MSCs. While the transfusion of MSC-secretome provided a significant therapeutic effect against ALF, it was marginally less effective than DEX treatment. Hepatic markers (ALT, ALP, GGT, and bilirubin) were improved more significantly in DEX-treated mice than in MSC-secretome treated group. This improvement was accompanied by marked relief in the oxidative assessed in the liver as Nrf-2, MDA, and GSH. Additionally, the normal levels of angiogenic (VEGF), and inflammatory (TNF-α) markers were effectively restored after DEX treatment. Also, both MSC-secretome and DEX resolved liver necrosis. In summary, these data suggest that dexamethasone demonstrates a better therapeutic effect than MSC-secretome in the treatment of ALF. Further studies are necessary to standardize MSC-secretome as an acellular therapeutic approach. 

Key words: BM-MSCs, dexamethasone, acute liver failure, hepatoma cells, paracetamol, inflammation

---

1. Al Ghrbawy NM, Afify RAAM, Dyaa N, El Sayed AA. Differentiation of bone marrow: Derived mesenchymal stem cells into hepatocyte-like cells. Indian J Hematol Blood Transfus. 2016; 32 (3): 276–283. DOI: 10.1007/s12288-015-0581-7.
2. Andrade AC, Wolf M, Binder HM, Gomes FG, Manstein F, Ebner-Peking P, Poupardin R, Zweigerdt R, Schallmoser K, Strunk D. Hypoxic conditions promote the angiogenic potential of human induced pluripotent stem cell-derived extracellular vesicles. Int J Mol Sci. 2021; 22 (8): 3890. DOI: 10.3390/ijms22083890.
3. Baldari S, Di Rocco G, Piccoli M, Pozzobon M, Muraca M, Toietta G. Challenges and strategies for improving the regenerative effects of mesenchymal stromal cell-based therapies. Int J Mol Sci. 2017; 18 (10): 2087. DOI: 10.3390/ijms18102087.
4. Baranovskii DS, Klabukov ID, Arguchinskaya NV, Yakimova AO, Kisel AA, Yatsenko EM, Ivanov SA, Shegay PV, Kaprin AD. Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. Stem Cell Invest. 2022; 9: 7. DOI: 10.21037/sci-2022-025.
5. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013; 369 (26): 2525–2534. DOI: 10.1056/nejmra1208937.
6. Caplan AI, Correa D. The MSC: An injury drugstore. Cell Stem Cell. 2011; 9 (1): 11–15. DOI: 10.1016/j.stem.2011.06.008.
7. Chiabotto G, Pasquino C, Camussi G, Bruno S. Molecular pathways modulated by mesenchymal stromal cells and their extracellular vesicles in experimental models of liver fibrosis. Front Cell Dev Biol. 2020; 8: 594794. DOI: 10.3389/fcell.2020.594794.
8. Di Trapani M, Bassi G, Midolo M, Gatti A, Kamga L, Cassaro A, Carusone R, Adamo A, Krampera M. Differential and transferable modulatory effects of mesenchymal stem cells derived from different tissues on T, B and NK cell functions. Sci Rep. 2016; 6: 24120. DOI: 10.1038/srep24120.
9. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther. 1996; 277 (1): 105–112. DOI: 10.1016/S0022-3565(25)12795-X.
10. Huang B, Cheng X, Wang H, Huang W, Hu ZG, Wang D, Zhang K, Zhang H, Xue Z, Da Y, Zhang N, Hu Y, Yao Z, Qiao L, Gao F, Zhang R. Mesenchymal stem cells and their secreted molecules predominantly ameliorate fulminant hepatic failure and chronic liver fibrosis in mice respectively. J Transl Med. 2016; 14: 45. DOI: 10.1186/s12967-016-0792-1.
11. Hu C, Li L. In vitro culture of isolated primary hepatocytes and stem cell-derived hepatocyte-like cells for liver regeneration. Protein Cell. 2015; 6 (8): 562–574. DOI: 10.1007/s13238-015-0180-2.
12. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012; 12 (5): 383–396. DOI: 10.1038/nri3209.
13. LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, Ferrara N. Angiogenesis-independent endothelial protection of liver: Role of VEGFR-1. 2003; 299 (5608): 890–893. DOI: 10.1126/science.1079562.
14. Lener T, Gimona M, Aigner L, Börger V, Buzas E, Camussi G, Chaput N, Chatterjee D, Court FA, del Portillo HA, O’Driscoll L, Fais S, Falcon-Perez JM, Felderhoff-Mueser U, Fraile L, Gho YS, Görgens A, Gupta RC, Hendrix A, Hermann DM, Hill AF, Hochberg F, Horn PA, de Kleijn D, Kordelas L, Kramer BW, Krämer-Albers EM, Laner-Plamberger S, Laitinen S, Leonardi T, Lorenowicz MJ, Lim SK, Lötvall J, Maguire CA, Marcilla A, Nazarenko I, Ochiya T, Patel T, Pedersen S, Pocsfalvi G, Pluchino S, Quesenberry P, Reischl IG, Rivera FJ, Sanzenbacher R, Schallmoser K, Slaper-Cortenbach I, Strunk D, Tonn T, Vader P, van Balkom BWM, Wauben M, El Andaloussi S, Théry C, Rohde E, Giebel B. Applying extracellular vesicles based therapeutics in clinical trials — an ISEV position paper. J Extracell Vesicles. 2015; 4 (1): 30087. DOI: 10.3402/jev.v4.30087.
15. Li H, Dai H, Li J. Immunomodulatory properties of mesenchymal stromal/stem cells: The link with metabolism. J Adv Res. 2023; 45: 15–29. DOI: 10.1016/j.jare.2022.05.012.
16. Noreen S, Maqbool I, Madni A. Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol. 2021; 894: 173854. DOI: 10.1016/j.ejphar.2021.173854.
17. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. 1999; 284 (5411): 143–147. DOI: 10.1126/science.284.5411.143.
18. Salama AN, Badr EAE, Holah NS, El Barbary AA, Hessien M. Conservative hypomethylation of mesenchymal stem cells and their secretome restored the follicular development in cisplatin-induced premature ovarian failure mice. Reprod Sci. 2024; 31 (4): 1053–1068. DOI: 10.1007/s43032-023-01389-4.
19. Seljeskog E, Hervig T, Mansoor MA. A novel HPLC method for the measurement of thiobarbituric acid reactive substances (TBARS). A comparison with a commercially available kit. Clin Biochem. 2006; 39 (9): 947–954. DOI: 10.1016/j.clinbiochem.2006.03.012.
20. Stravitz RT, Lee WM. Acute liver failure. 2019; 394 (10201): 869–881. DOI: 10.1016/S0140-6736(19)31894-X.
21. Sun H, Shi C, Ye Z, Yao B, Li C, Wang X, Qian Q. The role of mesenchymal stem cells in liver injury. Cell Biol Int. 2022; 46 (4): 501–511. DOI: 10.1002/cbin.11725.
22. Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: Toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017; 18 (9): 1852. DOI: 10.3390/ijms18091852.
23. Wang P, Cui Y, Wang J, Liu D, Tian Y, Liu K, Wang X, Liu L, He Y, Pei Y, Li L, Sun L, Zhu Z, Chang D, Jia J, You H. Mesenchymal stem cells protect against acetaminophen hepatotoxicity by secreting regenerative cytokine hepatocyte growth factor. Stem Cell Res Ther. 2022; 13 (1): 94. DOI: 10.1186/s13287-022-02754-x.
24. Wang YH, Chen EQ. Mesenchymal stem cell therapy in acute liver failure. Gut Liver. 2023; 17 (5): 674–683. DOI: 10.5009/gnl220417.
25. Xu Y, Zhou X, Wang X, Jin Y, Zhou L, Ye J. Progress of mesenchymal stem cells (MSCs) & MSC-exosomes combined with drug intervention in liver fibrosis. Biomed Pharmacother. 2024; 176: 116848. DOI: 10.1016/j.biopha.2024.116848.
26. Xuan X, Tian C, Zhao M, Sun Y, Huang C. Mesenchymal stem cells in cancer progression and anticancer therapeutic resistance. Cancer Cell Int. 2021; 21 (1): 595. DOI: 10.1186/s12935-021-02300-4.
27. Xue R, Meng Q. The management of glucocorticoid therapy in liver failure. Front Immunol. 2019; 10: 2490. DOI: 10.3389/fimmu.2019.02490.
28. Ye C, Li W, Li L, Zhang K. Glucocorticoid treatment strategies in liver failure. Front Immunol. 2022; 13: 846091. DOI: 10.3389/fimmu.2022.846091.
29. Zhou C, Bai XY. Strategies for the induction of anti-inflammatory mesenchymal stem cells and their application in the treatment of immune-related nephropathy. Front Med. 2022; 9: 891065. DOI: 10.3389/fmed.2022.891065.
30. Zhu M, Hua T, Ouyang T, Qian H, Yu B. Applications of mesenchymal stem cells in liver fibrosis: Novel strategies, mechanisms, and clinical practice. Stem Cells Int. 2021; 2021: 6546780. DOI: 10.1155/2021/6546780.